We found an increase in peripheral-blood lymphocytes bearing the T-cell-specific activation antigen Ta1 in 20 of 35 patients with progressive multiple sclerosis, 4 of 18 patients with stable or improving multiple sclerosis, 1 of 17 patients with other neurologic diseases, and 1 of 14 normal controls (P less than 0.0002, Fisher's exact test). No increases in two other markers of T-cell activation, T113 and the interleukin-2 receptor, were found. In the cerebrospinal fluid, patients with progressive multiple sclerosis (pleocytosis, 3.9 +/- 1.6 cells per cubic millimeter) had 42 +/- 3.0 per cent Ta1+ cells. In contrast, patients with other inflammatory central nervous system diseases (36 +/- 13 cells per cubic millimeter) had 9.6 +/- 1.8 per cent Ta1+ cells (P less than 0.01). In patients with other neurologic diseases without inflammation (0.7 +/- 0.16 cells per cubic millimeter), the percentage of Ta1+ cells was equivalent to that in patients with multiple sclerosis (39 +/- 5.4 per cent), although the absolute number was lower. There was a positive correlation between the presence of Ta1+ cells in the spinal fluid and blood of patients with other neurologic diseases, but not patients with multiple sclerosis. Less than 1 per cent of lymphocytes from the spinal fluid of patients with multiple sclerosis expressed interleukin-2 receptors, as compared with 9.8 per cent of cells from subjects with other inflammatory neurologic diseases (P less than 0.01). These results suggest that the T cells in the spinal fluid of patients with multiple sclerosis may be activated by a different mechanism or in a different temporal sequence from that in patients with other nervous system diseases. Furthermore, the increase in Ta1+ cells in the peripheral blood of patients with multiple sclerosis demonstrates systemic immune activation in the disease; monitoring such cells may provide an objective measure of abnormal immunologic activity.
This article has been cited by other articles:
Preller, V., Gerber, A., Wrenger, S., Togni, M., Marguet, D., Tadje, J., Lendeckel, U., Rocken, C., Faust, J., Neubert, K., Schraven, B., Martin, R., Ansorge, S., Brocke, S., Reinhold, D.
(2007). TGF-beta1-Mediated Control of Central Nervous System Inflammation and Autoimmunity through the Inhibitory Receptor CD26. J. Immunol.
178: 4632-4640
[Abstract][Full Text]
Pranzatelli, M. R., Travelstead, A. L., Tate, E. D., Allison, T. J., Moticka, E. J., Franz, D. N., Nigro, M. A., Parke, J. T., Stumpf, D. A., Verhulst, S. J.
(2004). B- and T-cell markers in opsoclonus-myoclonus syndrome: Immunophenotyping of CSF lymphocytes. Neurology
62: 1526-1532
[Abstract][Full Text]
Zabaleta, M, Marino, R, Borges, J, Camargo, B, Ordaz, P, De Sanctis, J B, Bianco, N E
(2002). Activity profile in multiple sclerosis: an integrative approach A preliminary report. Mult Scler
8: 343-349
[Abstract]
Ishii, T., Ohnuma, K., Murakami, A., Takasawa, N., Kobayashi, S., Dang, N. H., Schlossman, S. F., Morimoto, C.
(2001). CD26-mediated signaling for T cell activation occurs in lipid rafts through its association with CD45RO. Proc. Natl. Acad. Sci. USA
10.1073/pnas.211439098v1
[Abstract][Full Text]
Ho, L., Aytac, U., Stephens, L. C., Ohnuma, K., Mills, G. B., McKee, K. S., Neumann, C., LaPushin, R., Cabanillas, F., Abbruzzese, J. L., Morimoto, C., Dang, N. H.
(2001). In Vitro and in Vivo Antitumor Effect of the Anti-CD26 Monoclonal Antibody 1F7 on Human CD30+ Anaplastic Large Cell T-Cell Lymphoma Karpas 299. Clin. Cancer Res.
7: 2031-2040
[Abstract][Full Text]
Gestri, D, Baldacci, L, Taiuti, R, Galli, E, Maggi, E, Piccinni, M-P, Vergelli, M, Massacesi, L
(2001). Oligoclonal T cell repertoire in cerebrospinal fluid of patients with inflammatory diseases of the nervous system. J. Neurol. Neurosurg. Psychiatry
70: 767-772
[Abstract][Full Text]
Steinbrecher, A., Reinhold, D., Quigley, L., Gado, A., Tresser, N., Izikson, L., Born, I., Faust, J., Neubert, K., Martin, R., Ansorge, S., Brocke, S.
(2001). Targeting Dipeptidyl Peptidase IV (CD26) Suppresses Autoimmune Encephalomyelitis and Up-Regulates TGF-{{beta}}1 Secretion In Vivo. J. Immunol.
166: 2041-2048
[Abstract][Full Text]
Khoury, S. J., Guttmann, C. R. G., Orav, E. J., Kikinis, R., Jolesz, F. A., Weiner, H. L.
(2000). Changes in Activated T Cells in the Blood Correlate With Disease Activity in Multiple Sclerosis. Arch Neurol
57: 1183-1189
[Abstract][Full Text]
Ikushima, H., Munakata, Y., Ishii, T., Iwata, S., Terashima, M., Tanaka, H., Schlossman, S. F., Morimoto, C.
(2000). Internalization of CD26 by mannose 6-phosphate/insulin-like growth factor II receptor contributes to T cell activation. Proc. Natl. Acad. Sci. USA
97: 8439-8444
[Abstract][Full Text]
Zhang, G X, Baker, C M, Kolson, D L, Rostami, A M
(2000). Chemokines and chemokine receptors in the pathogenesis of multiple sclerosis. Mult Scler
6: 3-13
[Abstract]
Hohol, M. J, Olek, M. J, Orav, E J., Stazzone, L., Hafler, D. A, Khoury, S. J, Dawson, D. M, Weiner, H. L
(1999). Treatment of progressive multiple sclerosis with pulse cyclophosphamidel methylprednisolone: Response to therapy is linked to the duration of progressive disease. Mult Scler
5: 403-409
[Abstract]
Iwata, S., Yamaguchi, N., Munakata, Y., Ikushima, H., Lee, J. F., Hosono, O., Schlossman, S. F., Morimoto, C.
(1999). CD26/dipeptidyl peptidase IV differentially regulates the chemotaxis of T cells and monocytes toward RANTES: possible mechanism for the switch from innate to acquired immune response. Int Immunol
11: 417-426
[Abstract][Full Text]
Bongioanni, P., Lombardo, F., Moscato, G., Mosti, S., Meucci, G.
(1999). T-Cell Interferon Gamma Receptor Binding in Interferon Beta-1b-Treated Patients With Multiple Sclerosis. Arch Neurol
56: 217-222
[Abstract][Full Text]
Bongioanni, P., Mosti, S., Moscato, G., Lombardo, F., Manildo, C., Meucci, G.
(1999). Decreases in T-Cell Tumor Necrosis Factor {alpha} Binding With Interferon Beta Treatment in Patients With Multiple Sclerosis. Arch Neurol
56: 71-78
[Abstract][Full Text]
Wortsman, J., McConnachie, P., Tahara, K., Kohn, L. D.
(1998). Thyrotropin Receptor Epitopes Recognized by Graves' Autoantibodies Developing under Immunosuppressive Therapy. J. Clin. Endocrinol. Metab.
83: 2302-2308
[Abstract][Full Text]
Lozeron, P, Chabas, D, Duprey, B, Lyon-Caen, O, Liblau, R
(1998). T cell receptor Vb5 and Vb17 clonal diversity in cerebrospinal fluid and peripheral blood lymphocytes of multiple sclerosis patients. Mult Scler
4: 154-161
[Abstract]
Hanna, A. N., Waldman, W. J., Lott, J. A., Koesters, S. C., Hughes, A. M., Thornton, D. J.
(1997). Increased alkaline phosphatase isoforms in autoimmune diseases. Clin. Chem.
43: 1357-1364
[Abstract][Full Text]
Allegretta, M, Nicklas, J., Sriram, S, Albertini, R.
(1990). T cells responsive to myelin basic protein in patients with multiple sclerosis. Science
247: 718-721
[Abstract]
Ishii, T., Ohnuma, K., Murakami, A., Takasawa, N., Kobayashi, S., Dang, N. H., Schlossman, S. F., Morimoto, C.
(2001). CD26-mediated signaling for T cell activation occurs in lipid rafts through its association with CD45RO. Proc. Natl. Acad. Sci. USA
98: 12138-12143
[Abstract][Full Text]
